Nathaniel Wang
Chief Executive Officer & Co-Founder Replicate Bioscience
Dr. Nathaniel Wang is the Chief Executive Officer at Replicate Bioscience and cofounder of the company. He has over 15 years of leadership experience in immunology and drug development. He is a pioneer in synthetic, self-replicating RNA technologies and their delivery, including the development of the Replicate srRNA platform. He is also a recognized expert in the fields of immuno-oncology and infectious disease.
Prior to Replicate Bioscience, Dr. Wang was head of the RNA Medicines business unit at Synthetic Genomics, where he developed a self-replicating RNA platform asset. This asset and business unit was sold to Janssen in 2019. At Janssen, he setup a drug discovery and CMC framework and led teams developing compounds in multiple therapeutic spaces using the acquired technologies.
Seminars
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
- Optimizing self-replicating RNA vectors and manufacturing drive increases in immunogenicity and safety for a best-in-class therapeutic index
- Increased therapeutic index enable vaccines that target multiple respiratory pathogens and shorten development cycles
- srRNA are proving to enable a new class of vectorized biotherapeutics that enable multiplexed products with controllable PK profiles that can be re-dosed
